Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024).

Ignace  Vergote

Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Carrick Therapeutics (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Medical University of Vienna (Inst); Millennium (Inst); MSD Belgium (Inst); Octimet (Inst); Oncoinvent (Inst); PharmaMar (Inst); Roche (Inst); Roche (Inst); Sotio (Inst); Tesaro (Inst)

Research Funding - Amgen (Inst); Genmab (Inst); Oncoinvent (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD/Merck; Roche; Tesaro

Nicole  Concin

Consulting or Advisory Role - Seagen

Travel, Accommodations, Expenses - Genmab; Roche Belgium

Mansoor Raza  Mirza

Leadership - Karyopharm Therapeutics; SeraCare

Stock and Other Ownership Interests  - Karyopharm Therapeutics; SeraCare

Honoraria - Advaxis; AstraZeneca; Cerulean Pharma; Clovis Oncology; Novocure; Pfizer; Roche; tesaro

Consulting or Advisory Role - AstraZeneca; BioCad; Cerulean Pharma; Clovis Oncology; Genmab; Karyopharm Therapeutics; Novocure; Pfizer; Sotio; Tesaro

Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Pfizer (Inst); Tesaro (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro

Camilla Mondrup  Andreassen

Employment - Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk

Stock and Other Ownership Interests  - Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Chr. Hansen; Chr. Hansen; Chr. Hansen; Chr. Hansen; Chr. Hansen; Chr. Hansen; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Colgate Palmolive; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Coloplast; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Genmab; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Lundbeck; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Scandinavian Development Services ; Scandinavian Development Services ; Scandinavian Development Services ; Scandinavian Development Services ; Scandinavian Development Services ; Scandinavian Development Services ; Scandinavian Development Services ; Scandinavian Development Services ; Teva; Teva; Teva; Teva; Teva; Teva; Teva; Teva; Teva; Teva; Teva; Teva; Teva; Teva; Teva; Teva; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis; Veloxis

Domenica  Lorusso

Honoraria - AstraZeneca; Clovis Oncology; genmab; Immunogen; Merck; Roche; tesaro

Consulting or Advisory Role - PharmaMar

Speakers' Bureau - AstraZeneca; Clovis Oncology; pharmamar; tesaro

Research Funding - Clovis Oncology (Inst); Merck (Inst); PharmaMar (Inst); tesaro (Inst)

Expert Testimony - Clovis Oncology

Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche; TESARO

Christine N.  Gennigens

No Relationships to Disclose

Susana N.  Banerjee

Honoraria - Roche

Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Carrick Therapeutics (Inst); Clovis Oncology; GenMab; Merck; Roche; Seagen; Tesaro

Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Nucana

Roisin Eilish  O'Cearbhaill

Consulting or Advisory Role - GlaxoSmithKline; Tesaro

Research Funding - Genmab (Inst); Juno Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Regeneron (Inst); Sellas Life Sciences (Inst); Stem CentRx (Inst); TapImmune Inc. (Inst); TCR2 Therapeutics (Inst)

Susana  Campos

Honoraria - Clovis Oncology; Eisai; Tesaro

Consulting or Advisory Role - Clovis Oncology; Eisai; Tesaro

Research Funding - Clovis Oncology; Tesaro

Travel, Accommodations, Expenses - Clovis Oncology; Eisai; Tesaro

Leonardo  Viana Nicacio

Employment - Seagen

Stock and Other Ownership Interests  - Florence Healthcare; Seagen

Honoraria - Seagen

Travel, Accommodations, Expenses - Seagen

Lamar  Eaton

Employment - Genmab

David M.  O'Malley

Consulting or Advisory Role - Abbvie; Agenus; Ambry Genetics; AstraZeneca; Clovis Oncology; Eisai; Genelux; Genentech/Roche; GOG Foundation; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Leap Therapeutics; Marker Therapeutics; Novocure; OncoQuest; Tarveda Therapeutics; Tesaro; Translational Genomics Research Institute

Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Agenus (Inst); Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Genmab (Inst); Immunogen (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Leap Therapeutics (Inst); Merck (Inst); PharmaMar (Inst); Regeneron (Inst); Seagen (Inst); Tesaro (Inst); TRACON Pharma (Inst)

Ibrahima  Soumaoro

Employment - Genmab

Stock and Other Ownership Interests  - Bristol-Myers Squibb; Genmab

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genmab

Bradley J.  Monk

Leadership - US Oncology

Honoraria - Abbvie; Advaxis; Agenus; Amgen; AstraZeneca; ChemoCare; ChemoID; Clovis Oncology; Conjupro Biotherapeutics; Eisai; Geistlich Pharma; Genmab; Immunogen; Immunomedics; Incyte; Janssen; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; OncoQuest; Perthera; Pfizer; Precision Oncology; Puma Biotechnology; Roche/Genentech; Samumed; Takeda; Tesaro; VBL Therapeutics

Consulting or Advisory Role - Abbvie; Advaxis; Amgen; AstraZeneca; Cerulean Pharma; ChemoCare; ChemoID; Clovis Oncology; Eisai; Geistlich Pharma; Immunogen; Incyte; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; OncoMed; OncoSec; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Samumed; Takeda; Tesaro; VBL Therapeutics

Speakers' Bureau - AstraZeneca; Clovis Oncology; Janssen; Roche/Genentech; Tesaro

Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)